Berlin-based Cantourage offers fast-track access to the European medical cannabis market for international growers
BERLIN, June 16, 2021 / PRNewswire / – European medical cannabis company Cantourage today launched its innovative new platform, enabling growers around the world to bring their product to the growing and profitable European market faster and more efficiently. lower cost. Already a price leader with a significant market share in the competitive German Dronabinol market, Cantourage and its partners now offer products in all relevant market segments – dried flowers, extracts and Dronabinol.
“We look forward to expanding our offering with the launch of our platform, which starts with more than 10 partners from all continents. The current European market is dominated by a few companies. Market entrants face many obstacles when trying to enter these profitable markets. We empower growers and give them fast and secure access to the European market, while helping them grow their brand, ”comments Philip Schetter, co-CEO of Cantourage. “Our platform expands and improves the offer to patients and healthcare providers in Europe, both in terms of products and prices. Most importantly, Cantourage guarantees the highest European quality standards for flowers around the world. We are ready to revolutionize the market. added Dr Florian Holzapfel, co-founder of Cantourage.
Cantourage disrupts and shatters the current market oligopoly by providing quick, unbureaucratic access to the European market for cannabis growers around the world. The company allows growers to sell under their own brands. Thanks to its presence in various segments, Cantourage aims to democratize the market, to offer pharmacies and medical cannabis distributors alternative purchasing opportunities across the entire market offer and to create new opportunities for the market continues to grow. Based in Germany but already active in Europe in four countries, Cantourage is configured to evolve at high speed.
Norman Ruchholtz, co-CEO of Cantourage, said: “The European medical cannabis market is the fastest growing, with more than 20 European countries having already legalized medical cannabis and sales are expected to generate more than 3 billion dollars. dollars by 2025. About 1 to 2% of the population is estimated to be a potential patient of medical cannabis, but access to the European market for producers and supply for patients is still very limited, with a few players creating a quasi-oligopoly. customers – that this market is ripe for change and disruption. ”
More than 10 growers from all continents, from Jamaica to Portugal and Uruguay, have already signed up as partners and customers, with more expected to join in a few weeks. “Cantourage is one of the few players that can supply the market at high speed – taking advantage of its existing production and distribution networks. Our dried flower product Flos FOTMER T3h is already available in German pharmacies. Together with our investors, we will continue to develop our footprint and reach to serve additional markets, ”explains co-founder Patrick Hoffmann.
Recently, the already profitable company closed its Series B financing, led by its long-term partner Think.Health Ventures. Alongside all the previous investors, 10x Group joined the round of funding which was set at a high double-digit valuation in millions of euros.
“The management team at the helm of Cantourage is exceptional. Their over 25 years of experience, their in-depth understanding of the market, their exceptional setup and their focus on expanding the offerings in the market make us very happy to be on board.” explains Dr Florian Kainzinger, CEO of Think.Health Ventures, which was also the first venture capital firm in 2015 to invest in the medical cannabis sector in Germany.
Cantourage with its market disruption model and more than 10 signed supply contracts in place, is fast becoming one of the European leaders in medical cannabis.
Cantourage is one of the leading European medical cannabis companies. The Berlin-based company was founded in 2019 by industry pioneers Dr Florian Holzapfel, Norman Ruchholtz and Patrick Hoffman. Cantourage enables producers around the world to introduce their product to the growing and profitable European market faster and at lower cost, while ensuring and further developing the highest European quality standards. It offers products in all relevant market segments: dried flowers, extracts and Dronabinol, with a strong and growing market share in the latter.
Press contactKekst [email protected] Roland Leithaeuser + 49 162-207-4592
View original content to download multimedia:http://www.prnewswire.com/news-releases/berlin-based-cantourage-provides-fast-track-access-to-the-european-medical-cannabis-market-for-international-cultivators-301313778.html